Business
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health
About this update from Brainsway Ltd
[{"type":"image","alt":"BrainsWay","displaySize":"","headline":null,"caption":"BrainsWay","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":219,"url":"https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6QrLgY5gLW7VtP5hZFuKtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f","width":300,"height":219}},"lazy":false},{"type":"text","content":"BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care","length":170,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health Inc. (“BrainStim”), a provider based in British Columbia servicing a growing number of mental health clinics in Canada. Under the terms of the agreement, BrainsWay will invest $1.0 million initially, with potential for an additional $1.5 million via two milestone-based investments, for a minority position in BrainStim in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares.","length":791,"tagName":"p"},{"type":"text","content":"“Our investment in BrainStim is now the fifth minority-stake investment into growth-oriented clinical service platforms announced by the Company. These minority stake investments support our broader strategic initiative to expand access to and awareness of cutting-edge mental health interventions such as Deep TMS, while allowing BrainsWay to continue focusing on the scientific and clinical advancement of its technology, working to expand its range of cleared clinical indications, and delivering best-in-class support to all its customers,” said Hadar Levy, BrainsWay’s Chief Executive Officer.","length":598,"tagName":"p"},{"type":"text","content":"“As a long-time BrainsWay partner and an advocate for their dTMS technology, we are incredibly excited to link arms as we accelerate ...